GlassScriptPhysician profile
Melissa E Nunn
NPI 1992178859
$5,004.60
in general payments reported to CMS, 2019-2025
27 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $1,247 · 2023: $1,131 · 2024: $876 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.40 | 2021-2024 | |
| Abbott Laboratories | $441.31 | 2022-2025 | Freestyle Libre 3 |
| Genzyme Corporation | $370.44 | 2021-2025 | |
| Novo Nordisk INC | $368.53 | 2022-2025 | Wegovy |
| Gilead Sciences, INC. | $352.64 | 2022-2025 | Epclusa, Descovy |
| Teva Pharmaceuticals USA, INC. | $300.27 | 2022-2025 | Austedo Xr, Uzedy |
| Sanofi Pasteur INC. | $225.44 | 2022-2023 | |
| Dexcom, INC. | $154.25 | 2024 | Dexcom G7 Gss (161) |
| Janssen Biotech, INC. | $136.78 | 2025 | |
| Amgen INC. | $124.99 | 2022 | |
| Dermavant Sciences, INC. | $124.99 | 2023 | Vtama |
| Neurelis, INC. | $123.56 | 2024 | Valtoco |
| Pharmacyclics LLC, An Abbvie Company | $123.27 | 2021 | |
| Xeris Pharmaceuticals, INC. | $121.87 | 2023 | Gvoke Hypopen |
| Regeneron Healthcare Solutions, INC. | $121.83 | 2024 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $120.39 | 2023 | Quviviq |
| Sage Therapeutics, LLC | $118.36 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $118.03 | 2025 | Opsumit, Uptravi |
| Phadia US INC. | $111.60 | 2022 | |
| Agile Therapeutics, INC. | $111.37 | 2021 | |
| Medtronic, INC. | $111.03 | 2022 | |
| Phathom Pharmaceuticals, INC. | $101.66 | 2024 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2022 | |
| Impel Pharmaceuticals INC. | $99.99 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.06 | 2025 | |
| Lilly USA, LLC | $95.43 | 2024 | Zepbound |
| Neurocrine Biosciences, INC. | $94.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Nunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.